Search Within

Neil Jayendra Shah

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (10)
  2. Meeting Abstract (8)
Groups
  1. Department of Medicine (18)
  2. Department of Pathology and Laboratory Medicine (18)
  3. Genitourinary Oncology Service (18)
  4. Solid Tumor Oncology Division (18)
  5. Weinberg Fellows (13)
  6. Hematologic Malignancies, Division of (12)

More Groups

People
  1. Chung-Han Lee (10)
  2. Darren Feldman (10)
  3. Maria Carlo (10)
  4. Ritesh Kotecha (10)
  5. Martin Voss (9)
  6. Robert Motzer (9)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (4)
  4. 2022 (3)
  5. 2021 (3)
Publications
  1. Journal of Clinical Oncology (8)
  2. European Urology Oncology (2)
  3. Cancer (1)
  4. Cancers (1)
  5. Clinical Cancer Research (1)
  6. Current Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. Elsevier BV (2)
  3. MDPI (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. Mosby Elsevier (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immune checkpoint blockade response in mucinous tubular and spindle cell carcinoma
    Journal Article

    Makker, S.; Shah, N. J.; Carlo, M. I.; Kuo, F.; Hakimi, A. A.; Chen, Y. B.; Iyer, G.; Kotecha, R. R.
    Current Oncology (2025)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Checkpoint inhibitor-related skin reactions in cancer patients are characterized by unique rash specific immune responses
    Meeting Abstract

    Goleva, E.; Lacouture, M.; Lyubchenko, T.; Gu, S.; Xiao, O.; Kraehenbuehl, L.; Berdyshev, E.; Ketosugbo, K.; Moy, A.; Rotemberg, V.; more...
    Journal of Allergy and Clinical Immunology (2024)

    Fulltext@MSK | Save
  • Cabozantinib plus nivolumab in patients with non–clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Journal Article

    Fitzgerald, K. N.; Lee, C. H.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y.; Lefkowitz, R. A.; Shah, N. J.; Owens, C. N.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer
    Journal Article

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Chaim, J.; Chen, Y.; Jacobi, R.; Zucker, M.; Reznik, E.; McHugh, D.; Shah, N. J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save
  • Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways
    Journal Article

    Lacouture, M. E.; Goleva, E.; Shah, N.; Rotemberg, V.; Kraehenbuehl, L.; Ketosugbo, K. F.; Merghoub, T.; Maier, T.; Bang, A.; Gu, S.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Genomic ancestry in kidney cancer: Correlations with clinical and molecular features
    Journal Article

    Kotecha, R. R.; Knezevic, A.; Arora, K.; Bandlamudi, C.; Kuo, F.; Carlo, M. I.; Fitzgerald, K. N.; Feldman, D. R.; Shah, N. J.; Reznik, E.; more...
    Cancer (2024)

    Fulltext@MSK | Save
  • IL12/23 blockade with ustekinumab as a treatment for immune-related cutaneous adverse events
    Journal Article

    Gu, S. L.; Maier, T.; Moy, A. P.; Dusza, S.; Faleck, D. M.; Shah, N. J.; Lacouture, M. E.
    Pharmaceuticals (2023)

    Fulltext@MSK | Save
  • A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT)
    Meeting Abstract

    Funt, S. A.; Knezevic, A.; Freeman, B. A.; Bolos, M.; Martorana, V.; Donoghue, M.; Khan, S.; Singh, H.; Bromberg, M.; Quinlan, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save